Scientists hunt for clues to make CAR-T last longer in myeloma
NCT ID NCT07342179
First seen Jan 22, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This study looks at 60 adults with multiple myeloma who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in patients' blood before treatment and track how long the modified CAR-T cells persist afterward. The goal is to find early signs that predict a strong, lasting response, which could help doctors personalize treatment and improve outcomes for future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu de Poitiers
RECRUITINGPoitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.